Payment overview · 2025
General Payments
$662,710.71
62 reported records · 18 companies
Healthcare provider profile · identity verified
Jeffrey Chambers, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · MINNEAPOLIS, MN · NPI 1437192598
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Chambers, M.D. received $662,710.71 in general payments during 2025 across 62 reported records.
Teleflex LLC accounted for 98.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teleflex LLC | Unresolved — no canonical attribution shown | $650,449.94 | 98.2% | 4 | 2025 |
| ZOLL Circulation Inc | Unresolved — no canonical attribution shown | $7,926.80 | 1.2% | 10 | 2025 |
| Merit Medical Systems Inc | Unresolved — no canonical attribution shown | $1,717.48 | 0.3% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $745.15 | 0.1% | 8 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $470.18 | 0.1% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$277.36 | 0.0% | 5 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $210.47 | 0.0% | 3 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $187.13 | 0.0% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $180.60 | 0.0% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $170.45 | 0.0% | 5 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $122.05 | 0.0% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $89.19 | 0.0% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $53.65 | 0.0% | 3 | 2025 |
| Ancora Heart, Inc. | Unresolved — no canonical attribution shown | $33.29 | 0.0% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $24.01 | 0.0% | 1 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $21.15 | 0.0% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $16.30 | 0.0% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.51 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Royalty or License | $650,449.94 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,325.00 | 3 |
| Food and Beverage | $2,872.81 | 52 |
| Consulting Fee | $2,075.00 | 2 |
| Travel and Lodging | $987.96 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ARROW Normalized: arrow |
Device | Teleflex LLC | $650,449.94 | 4 | 2025 |
Source payment records
|
|||||
| Catheter Normalized: catheter |
Device | ZOLL Circulation Inc | $7,926.80 | 10 | 2025 |
Source payment records
|
|||||
| Downstream Cartridge Normalized: downstream cartridge |
Device | ZOLL Circulation Inc | $7,926.80 | 10 | 2025 |
Source payment records
|
|||||
| TherOx DS2 Console Normalized: therox ds2 console |
Device | ZOLL Circulation Inc | $7,926.80 | 10 | 2025 |
Source payment records
|
|||||
| Edwards SAPIEN 3 Ultra Transcatheter Heart Valve Normalized: edwards sapien 3 ultra transcatheter heart valve |
Device | Edwards Lifesciences Corporation | $364.96 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $264.07 | 3 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $215.25 | 2 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $210.47 | 3 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $187.13 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $180.60 | 3 | 2025 |
Source payment records
|
|||||
| Emerge Push Normalized: emerge push |
Device | Boston Scientific Corporation | $154.53 | 2 | 2025 |
Source payment records
|
|||||
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $133.98 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $122.98 | 2 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $122.05 | 1 | 2025 |
Source payment records
|
|||||
| NAVITOR Normalized: navitor |
Device | Abbott Laboratories | $94.49 | 2 | 2025 |
Source payment records
|
|||||
| EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Normalized: edwards sapien 3 transcatheter heart valve thv |
Device | Edwards Lifesciences Corporation | $87.58 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $68.60 | 3 | 2025 |
Source payment records
|
|||||
| AccuCinch Normalized: accucinch |
Device | Ancora Heart, Inc. | $33.29 | 1 | 2025 |
Source payment records
|
|||||
| NeuroBlate Robotic Probe Driver Normalized: neuroblate robotic probe driver |
Device | Boston Scientific Corporation | $31.80 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $27.93 | 1 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $23.41 | 1 | 2025 |
Source payment records
|
|||||
| Orsiro Mission Normalized: orsiro mission |
Device | BIOTRONIK INC. | $21.15 | 1 | 2025 |
Source payment records
|
|||||
| COREVALVE EVOLUT R Normalized: corevalve evolut r |
Device | Medtronic, Inc. | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER Normalized: flowtriever |
Device | Stryker Corporation | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| METACROSS OTW Normalized: metacross otw |
Device | Terumo Medical Corporation | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| TR BAND Normalized: tr band |
Device | Terumo Medical Corporation | $16.30 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| IGT Devices Undivided Normalized: igt devices undivided |
Device | Philips North America LLC | $15.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 283 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 228 | 79 |
| Clopidogrel | Clopidogrel Bisulfate | 189 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 155 | 53 |
| Losartan Potassium | Losartan Potassium | 140 | 42 |
| Atorvastatin Calcium | Atorvastatin Calcium | 124 | 49 |
| Eliquis | Apixaban | 111 | 39 |
| Lisinopril | Lisinopril | 104 | 38 |
| Furosemide | Furosemide | 97 | 39 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 37 |
| Nitroglycerin | Nitroglycerin | 85 | 48 |
| Carvedilol | Carvedilol | 72 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 68 | 30 |
| Warfarin Sodium | Warfarin Sodium | 56 | 19 |
| Potassium Chloride | Potassium Chloride | 52 | 17 |
| Atenolol | Atenolol | 38 | 11 |
| Bumetanide | Bumetanide | 37 | 15 |
| Ezetimibe | Ezetimibe | 32 | 13 |
| Simvastatin | Simvastatin | 30 | 12 |
| Jardiance | Empagliflozin | 28 | 12 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $662,710.71 · 62 records | Teleflex LLC | ARROW, ARTIX MT, AccuCinch, Barostim Neo System, CARDIOMEMS, COREVALVE EVOLUT R, CT THROMBECTOMY SYSTEM KIT, Catheter, Downstream Cartridge, EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV), ESPRIT, Edwards SAPIEN 3 Ultra Transcatheter Heart Valve, Emerge Push, FFRct, FLOWTRIEVER, FLOWTRIEVER CATHETER, S, General - Therapies, IGT Devices Undivided, METACROSS OTW, NAVITOR, NeuroBlate Robotic Probe Driver, ONYX FRONTIER, Orsiro Mission, Paradise Ultrasound Renal Denervation System, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TR BAND, TherOx DS2 Console, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error